We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

QIAGEN

Qiagen is a provider of sample and assay technologies for molecular diagnostics and applied testing, including comple... read more Featured Products: More products

Download Mobile App




Genetic Markers Found for Breast Cancer Brain Metastasis

By LabMedica International staff writers
Posted on 06 Mar 2014
Print article
Image: The Bioanalyzer RNA 6000 Nano LabChip Kit (Photo courtesy of Agilent Technologies).
Image: The Bioanalyzer RNA 6000 Nano LabChip Kit (Photo courtesy of Agilent Technologies).
The development of brain metastases from breast cancer depends on several prognostic factors, including younger age, ethnicity, and hormone receptor negative status.

Other factors include the presence of Breast cancer 1, early onset (BRCA1) germ-line mutations, and the expression of the epidermal growth factor receptor 2 (Her2/neu) proto-oncogene, all of which contribute to an increased rate of brain metastasis.

Scientists at the Translational Genomics Research Institute (Phoenix, AZ, USA) obtained 35 retrospective fresh-frozen samples of breast brain metastases from other institutes and as well as non-neoplastic brain samples, and10 non-neoplastic breast tissue specimens. A series of 50 early-stage breast cancer, grade 1 and 2, specimens were also obtained.

Genomic DNA (gDNA) was isolated from fresh-frozen tissue using the DNeasy Blood and Tissue Kit (Qiagen; Valencia, CA, USA) and total ribonucleic acid (RNA), including small RNA, was isolated using the mirVana miRNA Isolation Kit (Ambion; Austin, TX, USA). RNA samples were evaluated for integrity using the Bioanalyzer RNA 6000 Nano LabChip Kit on a Bioanalyzer 2400 (Agilent Technologies; Santa Clara, CA, USA). The team performed deep genomic profiling, integrating gene copy number, gene expression, and DNA methylation datasets on the collection of the 35 breast-brain metastases samples.

Some of the common genetic alterations identified in the study were gains and losses in chromosome 8, as well as cell proliferation and cell-cycle progression, key mechanisms of cancer caused by genetic alterations, linked to the genes Aurora A kinase (AURKA), Aurora B kinase (AURKB) and Forkhead box protein M1 (FOXM1). The authors concluded that genomic and epigenomic profiling of breast brain metastasis provided insight into the somatic events underlying this disease, which have potential in forming the basis of future therapeutic strategies. Using the PAM50 breast cancer intrinsic classifier, Luminal B, Her2+/ER negative, and basal-like tumors were identified as the most commonly represented breast cancer subtypes in the brain metastasis cohort.

Nhan L. Tran, PhD, an Associate Professor and senior coauthor of the study said, “This groundbreaking study sets the stage for more exacting exploration, using the latest genomic technologies and aimed at developing new therapies that could help the tens of thousands of patients who urgently need our help.” The study was published on January 29, 2014, in the journal Public Library of Science One.

Related Links:

Translational Genomics Research Institute
Qiagen
Ambion


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The revolutionary autonomous blood draw technology is witnessing growing demands (Photo courtesy of Vitestro)

Robotic Blood Drawing Device to Revolutionize Sample Collection for Diagnostic Testing

Blood drawing is performed billions of times each year worldwide, playing a critical role in diagnostic procedures. Despite its importance, clinical laboratories are dealing with significant staff shortages,... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.